Mirvaso

The active ingredient in Mirvaso is brimonidine tartrate. Brimonidine tartrate belongs to a class of medications known as alpha-2 adrenergic agonists. When applied topically to the skin, it causes blood vessels to narrow, reducing blood flow and skin redness.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Mirvaso. However, the following is a synopsis of the general guidelines for the use of Mirvaso:

• Mirvaso should be used exactly as prescribed at the application site. It is not meant for oral, ophthalmic, or intravaginal use.
• Using a pea-sized amount of Mirvaso Gel, apply a thin layer to affected areas of the face.
• Avoid applying to open wounds or sores on the skin, and do not apply more than what has been prescribed. Doing so could lead to adverse events such as bradycardia (slow heart rate) or hypotension (low blood pressure).

The most common side effects of Mirvaso seen in clinical trials include:

• Redness and flushing.
• Temporary skin burning sensation when applied.
• Skin irritation (contact dermatitis).

Some individuals may experience serious side effects while using Mirvaso. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Intolerable skin reactions or changes that do not improve with continued use, such as redness, flushing, or altered pigmentation.
• Signs of a serious allergic reaction such as a rash, hives, trouble breathing, and swelling of the face, lips, eyes, tongue, or throat.
• Increased risk of slow heart rate and low blood pressure (orthostatic hypotension).

These are not all of the possible side effects of Mirvaso. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Mirvaso, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including:

• Depression
• Problems with your heart or blood vessels
• Problems with dizziness
• Blood pressure problems
• History of stroke
• Cardiovascular disease
• Problems with circulation
• Raynaud’s phenomenon
• Dry mouth or Sjögren’s Syndrome
• Skin tightening or scleroderma
• Irritated skin or open wounds/sores
• Plans for laser procedures
• Are pregnant or plan to become pregnant
• Are breastfeeding or plan to breastfeed

Do not use Mirvaso if you have an allergy to brimonidine tartrate or any of the other ingredients in Mirvaso.

Brimonidine gel works quickly to combat facial erythema of rosacea, and its effects can last up to 12 hours.

When Mirvaso is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Anti-hypertensives such as alpha-2 agonists, beta-blockers, and cardiac glycosides
• Alcohol
• Barbiturates
• Opiates
• Sedatives
• Anesthetics
• Monoamine oxidase inhibitors (MAOIs)

Mirvaso is available as a brimonidine topical gel in a strength of 0.33%.

Mirvaso should be stored at room temperature, away from light and moisture, and out of reach of children. Serious adverse reactions may occur following accidental ingestion of Mirvaso by children.

Mirvaso is manufactured by the pharmaceutical company Galderma Laboratories.

Yes, there is a generic available for the brand-name Mirvaso.

Consult your doctor or pharmacist before starting, stopping, or changing medications while taking Mirvaso.

It is unknown if Mirvaso is safe in pregnancy. Talk to your doctor if you are already pregnant or if you have any plans to become pregnant. They will know or recommend what is best for you.

It is unknown if Mirvaso passes into the breast milk. Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. They will know or recommend what is best for you.